Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook [Yahoo! Finance]